RESUMEN
Since the outbreak of Corona Virus Disease 2019 (COVID-19) in Hubei province, the epidemic scale has increased rapidly, and no effective antiviral drug therapy has been identified yet. This study aimed to evaluate the adjuvant efficacy of Natural Herbal Medicine (NHM) combined with Western medicine in the treatment of COVID-19. We performed a retrospective, 1:1 matched, case-control study of the first cohort of hospitalized COVID-19-confirmed cases (January 17, 2020 to January 28, 2020). A total of 22 of the 36 confirmed patients were included in this study, split into two groups of 11: the NHM group (NHM combined standard Western medicine treatment) and control group (standard Western medicine treatment alone). All patients received appropriate supportive care and regular clinical and laboratory monitoring. Main evaluation indicators included improvement of clinical symptoms such as fever, cough and diarrhea after hospitalization; pathogen nucleic acid test result of respiratory tract and fecal specimens of the patient after hospitalization, and change of chest CT examination after hospitalization. The duration of fever in the NHM group ([Formula: see text] days) was significantly shorter than that in the control group ([Formula: see text] days) ([Formula: see text]). During the whole hospitalization period, the number of cases with diarrhea in the NHM group (two cases) was less than that in the control group (eight cases) ([Formula: see text]). Compared with the control group ([Formula: see text]), the duration for improvement (DI) of chest CT in the NHM group ([Formula: see text]) was significantly shorter ([Formula: see text]). Our results suggest that NHM could improve the clinical symptoms of COVID-19 patients and may be effective in treating COVID-19; thus, a larger, prospective, randomized, controlled clinical trial should be conducted to further evaluate the adjuvant efficacy of NHM in the treatment of COVID-19.
Asunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Fitoterapia/métodos , Preparaciones de Plantas/uso terapéutico , Neumonía Viral/tratamiento farmacológico , Adulto , Anciano , Betacoronavirus , COVID-19 , Estudios de Casos y Controles , China , Estudios de Cohortes , Terapia Combinada , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico por imagen , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Hospitalización , Humanos , Masculino , Medicina Tradicional China , Persona de Mediana Edad , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico por imagen , Estudios Retrospectivos , SARS-CoV-2 , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
The aim of this study was to evaluate the efficacy and safety of entecavir (ETV) combined treatment with adefovir (ADV) on chronic hepatitic B (CHB) patients who failed to respond to nucleotide (acid) analog (NA) treatment. On this basis, the possible factors in the combined treatment of these patients will be analyzed. The safety, biochemical index, and the possible factors that might affect the ETV and ADV combined treatment at different points in time were retrospectively analyzed. The biochemical index included the following: virological response, hepatitis B virus (HBV) DNA decline, primary nonresponse, biochemical response, and the hepatitis B virus E antigen/hepatitis B virus E antibody seroconversion rate. There were 94 CHB patients and compensated liver cirrhosis patients who received ETV plus ADV treatment for over 12 weeks after failure of treatment with NAs. The authors have also investigated 76 CHB patients (80.9%) and 18 hepatitis B cirrhosis patients (19.1%) in this study. The HBV DNA baseline was 4.4 ± 1.4 log10 IU/mL, and the positive rate of HBeAg before salvage treatment was 78.7% (74/94). The sample sizes were 94, 78, 42, 10, 6, and 1 for follow-up of 24, 48, 96, 144, 192, and 240 weeks, respectively. The virological responses (HBV DNA < 2 log10 IU/mL) and biochemical responses were 52.1%, 74.3%, and 90.4% and 63.1%, 61.6%, and 81.1%, respectively, at 24, 48, and 96 weeks, which showed significant differences (P < 0.001 and P < 0.005, respectively). The HBV DNA decline was presented as mean ± SEM, which were 1.53 ± 1.23, 1.75 ± 1.37, 2.07 ± 1.54, and 2.39 ± 1.77 log10 IU/mL at 12, 24, 48, and 96 weeks, respectively. They showed significant differences compared with the baseline (χ = 8.084, P < 0.05). The rate of primary nonresponse was 30.9% (29/94), and the primary treatment failure rates were 26.6% (25/94), 24.4% (19/78), and 4.8% (2/42) at 24, 48, and 96 weeks, respectively. They all have statistical difference (P = 0.011 < 0.05). There were 23 patients who experienced virological breakthrough after the HBV DNA levels were undetectable, whereas after follow-up for 12-24 weeks, the HBV DNA levels were back to undetectable again. ETV plus ADV treatment is an efficient and safe treatment for CHB and compensated liver cirrhosis patients who experienced NA treatment failure. The high quantity of baseline HBV DNA level is a risk factor for poor efficacy of salvage treatment.
Asunto(s)
Adenina/análogos & derivados , Antivirales/administración & dosificación , Guanina/análogos & derivados , Hepatitis B Crónica/tratamiento farmacológico , Organofosfonatos/administración & dosificación , Adenina/administración & dosificación , Adenina/efectos adversos , Adulto , Antivirales/efectos adversos , ADN Viral/sangre , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Guanina/administración & dosificación , Guanina/efectos adversos , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Hepatitis B Crónica/virología , Humanos , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/virología , Masculino , Persona de Mediana Edad , Organofosfonatos/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: To study the effect of Eupolyphaga fibrinolyric protein (EFP) on microvessel density (MVD) and the expression of vascular endthelial growth factor in transplantation S180 and H22 mice. METHODS: The MVD in tumor was measured with immunohistochemical SP method and the VEGF level in serum was measured with ELISA method. RESULTS: Compared with the control group, EFP could significantly reduce the microvessel density and decrease the expression of vascular endothelial growth factor. CONCLUSION: EFP has the effect of anti-angiogenesis.
Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Cucarachas , Proteínas de Insectos/farmacología , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Neovascularización Patológica , Factor A de Crecimiento Endotelial Vascular/sangre , Animales , Antígenos CD34/metabolismo , Carcinoma Hepatocelular/irrigación sanguínea , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Línea Celular Tumoral , Cucarachas/química , Relación Dosis-Respuesta a Droga , Células Endoteliales/metabolismo , Femenino , Inmunohistoquímica , Neoplasias Hepáticas/irrigación sanguínea , Masculino , Ratones , Microvasos/patología , Trasplante de Neoplasias , Sarcoma 180/irrigación sanguínea , Sarcoma 180/metabolismo , Sarcoma 180/patología , Factor A de Crecimiento Endotelial Vascular/metabolismoRESUMEN
BACKGROUND: Diethylene glycol (DEG) poisoning is life-threatening. The clinical characteristics of patients with liver disease exposed to intravenous DEG have not been clarified. METHODS: Sixty-four patients with moderate to severe liver disease exposed to DEG in China in 2006 were investigated. RESULTS: The daily exposure total dose was 3-6 mL of a 30% (v/v) mixture. Acute renal failure (ARF), the predominant clinical manifestation, occurred in 23.4% (15/64) of these patients. The average time to onset was 6.53 +/- 3.48 days after exposure to DEG. ARF could be differentiated from the hepatorenal syndrome that usually occurs in patients with severe liver disease. The occurrence of ARF was significantly related to pre-existing renal function abnormality, and was not influenced by the allele distribution of DEG-metabolizing enzyme. The liver function profiles did not significantly change after DEG exposure. CONCLUSIONS: ARF was the main clinical manifestation in this intravenous DEG poisoning accident. The influence of underlying liver disease on DEG poisoning or that of DEG exposure on liver disease has many implications.